GlassScriptPhysician profile
Mohammad A Sayeed
NPI 1700888500
$1,745.98
in general payments reported to CMS, 2019-2025
17 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.46 · 2020: $59.47 · 2021: $457 · 2022: $316 · 2023: $307 · 2024: $362 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $763.18 | 2020-2025 | Trelegy Ellipta, Nucala |
| Janssen Pharmaceuticals, INC | $219.51 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.09 | 2020-2023 | Spiriva Respimat |
| Amarin Pharma, INC. | $83.60 | 2019-2021 | |
| Boston Scientific Corporation | $78.08 | 2023 | Watchman Access System |
| Genzyme Corporation | $60.56 | 2024 | |
| Electromed, INC. | $54.60 | 2024 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $45.65 | 2021-2022 | |
| Inspire Medical Systems, INC. | $41.87 | 2024-2025 | Inspire |
| Kerecis Limited | $34.89 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Baxter Healthcare | $30.83 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Genentech USA, INC. | $28.26 | 2024 | Xolair |
| Astellas Pharma US INC | $24.24 | 2021 | |
| Mylan Specialty L.P. | $21.37 | 2024 | Yupelri |
| Verona Pharma, INC. | $19.89 | 2025 | Ohtuvayre |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.61 | 2025 | Caplyta |
| Gilead Sciences, INC. | $16.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Sayeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.